This leads to weakened efficacy or differential side effects of regulatory mechanisms observed in animal models (e.g., FXR agonists improving mouse MASLD) in human clinical trials (e.g., pruritus or exacerbated cholestasis in some human patients). The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.